Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Address: Fürj u. 2. , Budapest, H-1124 Budapest,Hungary
Tel: +36 1 381 0765
Web: http://www.hyd.hu/
HYD LLC. for Cancer Research and Drug Development was established for the research, development and worldwide marketing of pharmaceutical and consumer products based on the proprietary procedure, deuterium depletion, primarily for the prevention and treatment of various kinds of cancer and for exploration of new indication fields for the application of deuterium-depleted water (DDW). Different applications of deuterium depletion are protected by international patents.
In the early nineties, Hungarian molecular biologist, Gábor Somlyai, PhD recognized that the shortage of deuterium can cause significant changes in living organisms. The most important outcome of his research carried out with deuterium-depleted water (DDW) was that tumor cells proved to be extremely sensitive to the withdrawal of deuterium (D). Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and according to the latest results it can also influence other physiological processes like glucose metabolism.
Recently, pharmacological industry started to develop and commercialize deuterium-containing medicines. Strategic replacement of hydrogen atoms in therapeutics with deuterium could positively influence efficacy and side effect profiles of drugs.
HYD’s approach to deuterium depletion of water and other molecules has broad potential to enhance the effectiveness of the presently available oncotherapies and result in innovative new medicines and consumer products for the treatment and prevention of cancer and other (e.g. metabolic) diseases.
HYD LLC. is marketing and distributing several products with decreased deuterium content in food and medicinal product categories. For human consumption Preventa® deuterium-depleted carbonated drinking water brand is available with different D-contents. Considering the D concentration of natural waters (140-150 ppm at our latitude), Preventa® products’ deuterium concentration varies between 125 and 45 ppm as it is indicated on the label. The products are mainly targeted on tumorous patients under conventional treatments or in remission and health-conscious consumers mostly in the age group over 40. It is made of deuterium-depleted water, natural mineral water and carbon dioxide. Preventa® is a registered trademark of HYD LLC.
VETERA-DDW-25® is medicinal preparation for veterinary use for the adjuvant therapy of neoplastic diseases of household pets. This first deuterium-depleted drug was registered in 1999. The active agent is deuterium-depleted water (DDW; 25 ppm D). Vetera-DDW-25® is mostly applied to dogs and cats suffering from cancer.
Several editions of the book „Defeating cancer!” written by Gábor Somlyai PhD are available in different languages and can be ordered from the Hungarian and foreign publishers.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
The managing director of Wörwag Pharma Hungary, Dr. Éva Kádár depicts the company’s impressive evolution, highlighting the expansive network of neuropathy centers that they’ve helped establish all over Hungary and…
Soneas MD Jozsef Repasi discusses the shift back towards Central and Eastern Europe for contract manufacturing services, the company’s growth since separating from Ubichem, and his ambitions for Soneas to…
AmCham Hungary, one of the largest American Chambers of Commerce in Central and Eastern Europe, discusses their advocacy efforts, particularly highlighting the chamber’s recently established Healthy Nation Policy Task Force…
Hungary has long boasted a vibrant, skilled pharmaceutical industry that continues to attract the interest of local and multinational entities alike. This fact was highlighted today at the celebration of GlaxoSmithKline’s…
The managing director of CSL Behring Hungary, Attila Lukács, discusses the company’s recent establishment in Hungary, the strategic benefits the country offers, as well as his experience starting an affiliate…
Meda Pharma Hungary GM Dr. Laszlo Gaspar describes how the strategic shift from Rx to OTC has allowed the company to experience year-on-year growth over the last eight years and…
The country manager of Berlin-Chemie / A. Menarini Hungary, Dr. Peter Olah, explains the impact of a more targeted sales force in driving the company in the last three years,…
Agnès Ducrot and Miklos Maróthy of CCI France Hongrie discuss their advocacy efforts in Hungary and the history of French investment in the country. They also discuss the challenges and opportunities…
The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that pharmaceutical companies approach the market, placing a much…
Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is striving to close with Tresiba and Xultophy,…
The managing director of Janssen Hungary, Andreas Woitossek, depicts the valuable role of real-world evidence in enabling the affiliate’s consistent double-digit growth over the last four years, while highlighting the…
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
See our Cookie Privacy Policy Here
